Skip to main content
. Author manuscript; available in PMC: 2018 Jul 27.
Published in final edited form as: Pancreas. 2015 Mar;44(2):190–197. doi: 10.1097/MPA.0000000000000255

Table 1.

Patient characteristics and pCT changes.

Patient characteristic
Gender
    Male 17 (44%)
    Female 22 (56%)
Age (Mean, SD) 56 (12.6)
Grade
    Low 24 (62%)
    Intermediate 13 (33%)
    FNA only 2 (5%)
Primary site
    Lung 2 (5%)
    Pancreas 13 (33%)
    Small bowel 13 (33%)
    Rectum 2 (5%)
    Unknown 9 (23%)
Prior therapy
    Surgery 6 (15%)
    Chemotherapy 6 (15%)
    Radiotherapy 1 (3%)
    Somatostatin analogue 18 (46%)
Concurrent
    Somatostatin analogue 12 (31%)
Disease at entry
    Progressive 29 (74%)
    Not progressive* 10 (26%)
*

9 of 10 patients not in progression at study entry had high tumor burden with sum of RECIST target lesion diameters greater than 15 cm at baseline. Mean of sum of RECIST target lesion diameters among patient not in progression was 27 cm (SD 21).